CY1113114T1 - Αναστολεις των ενζυμων ενεργοποιησης ε1 - Google Patents
Αναστολεις των ενζυμων ενεργοποιησης ε1Info
- Publication number
- CY1113114T1 CY1113114T1 CY20121100890T CY121100890T CY1113114T1 CY 1113114 T1 CY1113114 T1 CY 1113114T1 CY 20121100890 T CY20121100890 T CY 20121100890T CY 121100890 T CY121100890 T CY 121100890T CY 1113114 T1 CY1113114 T1 CY 1113114T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- inhibitors
- disorders
- activation enzymes
- enzymes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76448706P | 2006-02-02 | 2006-02-02 | |
EP07763239A EP1989206B1 (en) | 2006-02-02 | 2007-01-31 | Inhibitors of e1 activating enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113114T1 true CY1113114T1 (el) | 2016-04-13 |
Family
ID=38180115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100890T CY1113114T1 (el) | 2006-02-02 | 2012-09-28 | Αναστολεις των ενζυμων ενεργοποιησης ε1 |
Country Status (28)
Country | Link |
---|---|
US (6) | US8207177B2 (pt) |
EP (2) | EP2402334B1 (pt) |
JP (6) | JP5231251B2 (pt) |
KR (2) | KR101450533B1 (pt) |
CN (4) | CN110003216A (pt) |
AR (1) | AR059308A1 (pt) |
AU (1) | AU2007212648C1 (pt) |
BR (1) | BRPI0707493B8 (pt) |
CA (1) | CA2639924C (pt) |
CY (1) | CY1113114T1 (pt) |
DK (1) | DK1989206T3 (pt) |
EA (2) | EA031335B1 (pt) |
ES (2) | ES2390921T3 (pt) |
HK (2) | HK1124609A1 (pt) |
HR (1) | HRP20120786T1 (pt) |
IL (2) | IL193141A (pt) |
MY (2) | MY171289A (pt) |
NO (1) | NO342745B1 (pt) |
NZ (1) | NZ570084A (pt) |
PH (1) | PH12013501772A1 (pt) |
PL (1) | PL1989206T3 (pt) |
PT (1) | PT1989206E (pt) |
RS (1) | RS52437B (pt) |
SG (1) | SG169369A1 (pt) |
SI (1) | SI1989206T1 (pt) |
TW (2) | TW201509938A (pt) |
WO (1) | WO2007092213A2 (pt) |
ZA (1) | ZA200806402B (pt) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
CN110003216A (zh) * | 2006-02-02 | 2019-07-12 | 千禧药品公司 | E1活化酶抑制剂 |
GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
MY146645A (en) | 2006-04-21 | 2012-09-14 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
SI2049491T1 (sl) * | 2006-08-08 | 2011-05-31 | Millennium Pharm Inc | Heteroarilne spojine uporabne kot inhibitorji e1 aktivirajoäśih encimov |
US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
AU2007316715A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
AU2013204618B2 (en) * | 2007-08-02 | 2015-11-05 | Takeda Pharmaceutical Company Limited | Process for the synthesis of E1 activating enzyme inhibitors |
MX2010001126A (es) | 2007-08-02 | 2010-03-01 | Millennium Pharm Inc | Proceso para la sintesis de inhibidores de enzima de activacion de e1. |
EA201000614A1 (ru) * | 2007-10-17 | 2010-10-29 | Новартис Аг | Производные пурина как лиганды аденозинового рецептора а |
JP2012503651A (ja) * | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 3−デアザネプラノシン誘導体 |
UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
KR20170102381A (ko) * | 2009-05-14 | 2017-09-08 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | ((1s,2s,4r)4{4〔(1s)2,3디하이드로1h인덴1일아미노〕7h피롤로〔2,3d〕피리미딘7일}2하이드록시사이클로펜틸)메틸 설파메이트의 하이드로클로라이드 염 |
JP2013541587A (ja) * | 2010-11-05 | 2013-11-14 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Nedd8活性化酵素阻害剤の投与 |
SI2646444T1 (sl) | 2010-12-03 | 2016-09-30 | Epizyme, Inc. | Substituirane spojine purina in 7-deazapurina kot modulatorji epigenetskih encimov |
EP2646441B1 (en) * | 2010-12-03 | 2015-12-02 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
AU2012204843A1 (en) * | 2011-01-07 | 2013-05-02 | Leo Pharma A/S | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
WO2012158789A2 (en) | 2011-05-17 | 2012-11-22 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
KR101230678B1 (ko) | 2011-06-22 | 2013-02-07 | 이화여자대학교 산학협력단 | E1 활성화 억제제인 mln4924의 제조방법 |
EP3323414A1 (en) | 2011-08-24 | 2018-05-23 | Millennium Pharmaceuticals, Inc. | Inhibitors of nedd8-activating enzyme |
EP2764121A4 (en) * | 2011-10-07 | 2015-09-02 | Millennium Pharm Inc | E1 ENZYME MUTANTS AND USES THEREOF |
JP6238900B2 (ja) | 2011-10-28 | 2017-11-29 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Nae阻害物質に対する応答のバイオマーカー |
WO2013067396A2 (en) | 2011-11-03 | 2013-05-10 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
US9290500B2 (en) * | 2012-02-17 | 2016-03-22 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
CA2880813A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | Indole-substituted pyrrolopyrimidinyl inhibitors of uba6 |
EP2882750A4 (en) | 2012-08-10 | 2016-08-17 | Epizyme Inc | INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF |
AU2013312319B2 (en) | 2012-09-06 | 2018-04-19 | Epizyme, Inc. | Method of treating leukemia |
JP6486826B2 (ja) | 2012-10-01 | 2019-03-20 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用 |
JP2016517426A (ja) | 2013-03-15 | 2016-06-16 | エピザイム,インコーポレイティド | 置換プリン化合物の合成方法 |
EP2996773B1 (en) | 2013-05-14 | 2020-09-16 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents |
JP6378759B2 (ja) * | 2013-07-02 | 2018-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Sumo活性化酵素阻害剤として有用なヘテロアリール化合物 |
WO2015013256A1 (en) * | 2013-07-22 | 2015-01-29 | Baylor College Of Medicine | Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment |
HUE037266T2 (hu) | 2014-06-24 | 2018-08-28 | Taiho Pharmaceutical Co Ltd | Új pirrolopirimidinvegyületek vagy sóik, az azokat tartalmazó gyógyászati készítmény, különösen NAE inhibitor hatáson alapuló tumorok stb. megelõzésére és/vagy kezelésére szolgáló szer |
EP3901159A1 (en) * | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
WO2016069392A1 (en) * | 2014-10-29 | 2016-05-06 | Millennium Pharmaceuticals, Inc. | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents |
PT3244891T (pt) | 2015-01-16 | 2022-10-20 | Massachusetts Gen Hospital | Compostos para melhorar o splicing do arnm |
PE20171517A1 (es) | 2015-03-13 | 2017-10-20 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac 8 |
CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
KR101927375B1 (ko) * | 2016-04-20 | 2018-12-11 | 한국화학연구원 | 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN106008394B (zh) * | 2016-05-23 | 2018-12-04 | 中国人民解放军第二军医大学 | 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途 |
CN106854208B (zh) * | 2016-11-25 | 2019-04-09 | 成都柏睿泰生物科技有限公司 | 肿瘤抑制剂mln4924的合成方法 |
WO2019060536A1 (en) * | 2017-09-21 | 2019-03-28 | Millennium Pharmaceuticals, Inc. | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
WO2019109016A1 (en) | 2017-12-01 | 2019-06-06 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
EP3787663A4 (en) * | 2018-05-03 | 2022-03-09 | Her Majesty The Queen In Right of Canada as represented by The Minister of Health | SMALLPOXVIRUS HOST ZONE PROTEIN K3 AS A POSITIVE SELECTIVE MARKER FOR GENERATING RECOMBINANT SMALLPOXVIRUS, THERAPEUTIC TARGET FOR SMALLPOXVIRUS INFECTION AND THERAPEUTIC AGENT FOR PKR-RELATED DISEASES |
CA3105947A1 (en) * | 2018-07-09 | 2020-01-16 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies |
EP3820533A2 (en) * | 2018-07-13 | 2021-05-19 | IL-2RX, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
CN112079836B (zh) * | 2019-06-13 | 2022-12-13 | 中国科学院上海药物研究所 | 三唑并嘧啶类化合物及其盐、组合物和应用 |
BR112022016614A2 (pt) * | 2020-02-21 | 2022-12-13 | Mitokinin Inc | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais |
CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
WO2022040180A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
WO2022112951A1 (en) | 2020-11-25 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
CN112851671B (zh) * | 2021-02-08 | 2022-03-29 | 南京思聚生物医药有限公司 | 一种4-取代的吡啶并[2,3-d]嘧啶-7-酮类化合物及其制备方法和应用 |
CN112939971B (zh) * | 2021-02-08 | 2023-01-24 | 南京易腾药物研究院有限公司 | 一种香豆素类化合物及其制备方法和应用 |
WO2023023671A1 (en) * | 2021-08-20 | 2023-02-23 | Mitokinin, Inc. | Compositions and methods for treatment of neurodegenerative and mitochondrial disease |
WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
WO2024067676A1 (zh) * | 2022-09-30 | 2024-04-04 | 微境生物医药科技(上海)有限公司 | 作为sumo活化酶抑制剂的化合物 |
WO2024099438A1 (zh) * | 2022-11-11 | 2024-05-16 | 微境生物医药科技(上海)有限公司 | 作为sumo活化酶抑制剂的化合物 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622561A (en) * | 1969-08-18 | 1971-11-23 | Univ Utah | Nucleoside sugar esters of sulfamic acid and method for preparation of the same |
JPS62108897A (ja) | 1985-11-05 | 1987-05-20 | Rikagaku Kenkyusho | アスカマイシン誘導体及びその合成法並びに制癌剤 |
GB8813148D0 (en) | 1988-06-03 | 1988-07-06 | Glaxo Group Ltd | Chemical compounds |
GB8826205D0 (en) * | 1988-11-09 | 1988-12-14 | Wellcome Found | Heterocyclic compounds |
US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
US5763596A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
US5726302A (en) * | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
GB9325810D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
GB9325809D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
US6210917B1 (en) * | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US5973161A (en) * | 1996-03-18 | 1999-10-26 | The University Of North Carolina At Chapel Hill | Enantioselective synthesis of cyclopentenes |
US5824657A (en) * | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
US6734283B1 (en) * | 1997-12-19 | 2004-05-11 | Millennium Pharmaceuticals, Inc. | Human proteins responsible for NEDD8 activation and conjugation |
JPH11228422A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
JPH11228446A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
EP1411954B1 (en) | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
EP2198867A1 (en) | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
AU2003248708A1 (en) | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
US7915293B2 (en) * | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
WO2006002284A1 (en) * | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
ES2390803T3 (es) * | 2005-02-04 | 2012-11-16 | Millennium Pharmaceuticals, Inc. | Inhibidores de las enzimas activadoras E1 |
CN110003216A (zh) * | 2006-02-02 | 2019-07-12 | 千禧药品公司 | E1活化酶抑制剂 |
-
2007
- 2007-01-31 CN CN201910117672.3A patent/CN110003216A/zh active Pending
- 2007-01-31 PT PT07763239T patent/PT1989206E/pt unknown
- 2007-01-31 SG SG201100750-7A patent/SG169369A1/en unknown
- 2007-01-31 CN CN201610326315.4A patent/CN106008512B/zh active Active
- 2007-01-31 ES ES07763239T patent/ES2390921T3/es active Active
- 2007-01-31 WO PCT/US2007/002560 patent/WO2007092213A2/en active Application Filing
- 2007-01-31 EP EP11166220.1A patent/EP2402334B1/en active Active
- 2007-01-31 SI SI200731029T patent/SI1989206T1/sl unknown
- 2007-01-31 AU AU2007212648A patent/AU2007212648C1/en not_active Ceased
- 2007-01-31 RS RS20120419A patent/RS52437B/en unknown
- 2007-01-31 KR KR1020087020864A patent/KR101450533B1/ko active IP Right Grant
- 2007-01-31 EP EP07763239A patent/EP1989206B1/en active Active
- 2007-01-31 EA EA201500769A patent/EA031335B1/ru not_active IP Right Cessation
- 2007-01-31 KR KR1020147008025A patent/KR101450535B1/ko active IP Right Grant
- 2007-01-31 EA EA200801784A patent/EA024006B1/ru not_active IP Right Cessation
- 2007-01-31 MY MYPI2013003308A patent/MY171289A/en unknown
- 2007-01-31 CN CN200780004410.1A patent/CN101379061B/zh active Active
- 2007-01-31 JP JP2008553310A patent/JP5231251B2/ja not_active Expired - Fee Related
- 2007-01-31 ES ES11166220.1T patent/ES2593433T3/es active Active
- 2007-01-31 DK DK07763239.6T patent/DK1989206T3/da active
- 2007-01-31 BR BRPI0707493A patent/BRPI0707493B8/pt not_active IP Right Cessation
- 2007-01-31 NZ NZ570084A patent/NZ570084A/en not_active IP Right Cessation
- 2007-01-31 CN CN2013101694424A patent/CN103288835A/zh active Pending
- 2007-01-31 PL PL07763239T patent/PL1989206T3/pl unknown
- 2007-01-31 MY MYPI20082915A patent/MY158106A/en unknown
- 2007-01-31 US US11/700,614 patent/US8207177B2/en active Active - Reinstated
- 2007-01-31 CA CA2639924A patent/CA2639924C/en not_active Expired - Fee Related
- 2007-02-02 TW TW103118125A patent/TW201509938A/zh unknown
- 2007-02-02 TW TW096103917A patent/TWI510486B/zh not_active IP Right Cessation
- 2007-02-02 AR ARP070100458A patent/AR059308A1/es active IP Right Grant
-
2008
- 2008-07-23 ZA ZA2008/06402A patent/ZA200806402B/en unknown
- 2008-07-30 IL IL193141A patent/IL193141A/en active IP Right Grant
- 2008-08-19 NO NO20083581A patent/NO342745B1/no not_active IP Right Cessation
-
2009
- 2009-04-27 HK HK09103865.7A patent/HK1124609A1/xx not_active IP Right Cessation
- 2009-04-27 HK HK12106507.9A patent/HK1166308A1/zh not_active IP Right Cessation
-
2012
- 2012-06-19 US US13/527,018 patent/US20130165457A9/en not_active Abandoned
- 2012-06-19 US US13/526,946 patent/US20120258927A1/en not_active Abandoned
- 2012-09-28 CY CY20121100890T patent/CY1113114T1/el unknown
- 2012-10-02 HR HRP20120786TT patent/HRP20120786T1/hr unknown
-
2013
- 2013-02-15 JP JP2013027485A patent/JP2013103941A/ja not_active Withdrawn
- 2013-03-14 US US13/828,953 patent/US20130289037A1/en not_active Abandoned
- 2013-08-27 PH PH12013501772A patent/PH12013501772A1/en unknown
-
2014
- 2014-05-25 IL IL232786A patent/IL232786A/en active IP Right Grant
- 2014-11-26 JP JP2014238578A patent/JP6199851B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-24 JP JP2016103009A patent/JP2016147913A/ja not_active Withdrawn
- 2016-07-20 US US15/214,930 patent/US20170136024A1/en not_active Abandoned
-
2017
- 2017-11-24 JP JP2017225707A patent/JP2018027986A/ja not_active Withdrawn
-
2018
- 2018-09-19 US US16/135,380 patent/US20190255052A1/en not_active Abandoned
-
2019
- 2019-12-04 JP JP2019219430A patent/JP2020055841A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113114T1 (el) | Αναστολεις των ενζυμων ενεργοποιησης ε1 | |
CY1113166T1 (el) | Αναστολεις των ενζυμων ενεργοποιησης ε1 | |
CY1111121T1 (el) | Ετεροαρυλο ενωσεις χρησιμες ως αναστολεις ενζυμων ενεργοποiησης ε1 | |
CY1120154T1 (el) | Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1 | |
EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
UA100007C2 (ru) | Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит | |
EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
MA32811B1 (fr) | Nouveaux composés | |
NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
MY155695A (en) | Quinoxalinedione derivatives | |
CL2009000727A1 (es) | Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras. | |
CY1111240T1 (el) | Παραγωγα ετεροαρυλουριας χρησιμα για την αναστολη της chk1 | |
BRPI0914305B8 (pt) | compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos | |
EA200801211A1 (ru) | Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах | |
BRPI0413982A (pt) | derivados de alfa-aminoamida úteis como agentes anti-inflamatórios | |
EA200701835A1 (ru) | Амидные производные в качестве лигандов ионных каналов, их фармацевтические композиции и способы их применения | |
CY1117435T1 (el) | Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1 | |
CY1115351T1 (el) | Πυριμιδινονες ως αναστολεις ρi3κ | |
CY1114825T1 (el) | Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων | |
MY143583A (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
CY1114592T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις κινασης pim | |
CY1117513T1 (el) | Παραγωγα υδαντοïνης ως αναστολεις κυτταρικης νεκρωσης | |
CY1114555T1 (el) | Αναστολεις της c-met πρωτεϊνοκινασης τυπου αμινοπυραζολο τριαζολοθειαδιαζολιου | |
CY1115799T1 (el) | 1,2,5-οξαδιαζολια ως αναστολεις 2,3-διοξυγενασης ινδολοαμινης |